Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age - Summary - MDSpire
Advertisement
Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age
To evaluate the safety and immunogenicity of the mRNA-CR-04 vaccine in adults aged 18 to 49, including the assessment of neutralizing titers.
Key Findings:
The mRNA-CR-04 vaccine was generally well tolerated with mostly mild to moderate adverse events, indicating a favorable safety profile.
Grade 3 reactogenicity was observed only in the 100 µg group (16.7%), suggesting dose-dependent effects.
All doses elicited significant neutralizing titers against the BA.5 variant and cross-neutralizing titers against the wild type variant, highlighting the vaccine's potential effectiveness.
Neutralizing titers waned by Month 6 but remained above baseline levels, indicating sustained immune response.
Interpretation:
The mRNA-CR-04 vaccine demonstrated a favorable safety profile and robust immune response, supporting further investigation.
Limitations:
The study involved a small sample size, which may limit the generalizability of the findings.
Long-term safety and efficacy data are still needed to fully understand the vaccine's performance.
Conclusion:
The mRNA-CR-04 vaccine is a promising candidate for further development against SARS-CoV-2 variants.
